Central Processing of Odour Stimuli in Patients With Multi-systemic Functional Somatic Disorder, Multiple Chemical Sensitivityor Post Covid Compared to Healthy Controls - the Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- "Fingerprinting"
研究概览
简要总结
Background:
Functional somatic disorders (FSD) are frequent in all medical settings and characterized by persistent physical symptoms that cannot be explained by other somatic or psychiatric conditions. In recent decades, a number of different types of functional somatic disorders have been defined, but so far there is no clear explanation for the pathophysiology.
The high prevalence of olfactory problems in some patients with FSD suggests that olfactory symptoms are a potential diagnostic biomarker, especially in patients with multiple chemical sensitivity (MCS) and/ or post-covid.
The olfactory system is a unique sense with direct pathways to the limbic system, which is associated with emotion and mood. The focus on the olfactory system has revealed a significant association of this sense with numerous diseases.
Hypotheses:
- Patients with MCS and FSD have normal olfactory tests (normosmic subjects according to TDI score using "sniffing test") but differ in habituation test compared to healthy controls.
- MCS, post-covid and FSD patients have different odour perception processing in the brain as a "fingerprint" of functional somatic disorder compared to healthy controls.
Research plan:
The aim of this parts of the study is to identify specific MRI and paraclinical measures for MCS, post covid and BDS. In the first phase, 5 patients with MCS and 5 healthy controls will have a full clinical test of the olfactory system at the Flavour Institute, AU. In addition, they will be scanned (for "fingerprinting") where the investigators expect to find changes in olfactory connectivity similar to those seen in depression. This phase of the study will lead to a conclusion on the exact MR parameters to be used in the main study. In the second phase of the study, 10 patients with MCS, 10 with post-covid, 10 with FSD, and 10 healthy controls will be evaluated using a test battery of questionnaires and paraclinical tests.
Perspectives:
Previous imaging studies have focused on pain stimulation paradigms, rest-state fMRI, and DTI, but the olfactory system may be the "missing link" in identifiying a quantitative candidate in terms of whole-brain computational modeling and could potentially be used as a "fingerprint" in diagnosis and treatment monitoring.
详细描述
Background:
Functional somatic disorders (FSDs) are frequent in all medical settings and characterized by persistent physical symptoms that cannot be explained by other somatic or psychiatric conditions. Numerous terms have been used for the phenomenon, such as medically unexplained symptoms, somatoform disorders, and functional somatic syndromes (FSS). Various types of FSS exist, including chronic fatigue syndrome, myalgic encephalopathy, fibromyalgia, irritable bowel syndrome, and multiple chemical sensitivity (MCS), however previous studies suggest significant overlaps among most of them.
Based on empirical research, a phenotype of multi-systemic FSD or multi-organ bodily distress syndrome (multi-organ BDS) has been identified in the most severely affected patients who have symptoms from multiple organ systems, thus fulfilling the criteria for multiple FSS. Multi-organ BDS is a research diagnosis, and the terms FSD and BDS are used as synonyms. This diagnosis is defined by an identifiable physical symptom pattern with symptoms from four groups (a cardiopulmonary, a gastrointestinal, a musculoskeletal, and a general symptom group). The diagnosis has been included in the draft of WHO's ICD-11 for Primary Health Care under the name Bodily Stress Disorder. Multiple chemical sensitivity (MCS) is non-allergic and falls within the following two diagnostic categories: FSS and single-organ BDS. MCS is characterized by odour intolerance and various somatic symptoms attributed to the influence of toxic environmental chemicals in low usually harmless doses. Post-covid is charcterised by WHO by as continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation. the symptoms includefatigue, shortness of breath and cognitive dysfunction over 200 different symptoms have been reported that can have an impact on everyday functioning.The studies conducted by Per Fink and colleagues in recent years imply a high prevalence of FSD (about 10%) in the Danish population, and that FSD is associated with severe individual and social consequences.
There is no clear explanation for the pathophysiology of FSD. Numerous hypotheses for the aetiology of FSD and MCS exist, including inflammation, immune system involvement, central sensitization, mental or physical lifelong stress, and hyperactivity of the autonomic nervous system, but recent studies raise a neurobiological basis in this issue. However, most neuroscientific studies lack generalizability due to a gap in the delimitation of FSD, which makes it difficult to treat FSDs adequately.
Hypotheses concerning odour intolerance include stressors of the olfactory system and immunological sensitization. Clinical observations indicate that hypersensitivity to olfactory stimuli is also at play in patients with BDS, and a study indicates that this also applies to patients with functional motor disorders.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Female patients and healthy controls 18-70 years old.
- •Patients with moderate or severe MCS or multi-organ BDS or post-covid.
- •Symptoms present >6 months.
- •Written and verbal informed consent and letter of authority.
排除标准
- •Before the beginning of the study; Current sinonasal illness or upper respiratory tract allergy.
- •Serious or unstable medical illness (e.g. Apoplexy, Parkinson's, Alzheimer's disease, ischemic extremity pain, renal failure, liver failure, epilepsy, and Raynaud's phenomenon) that is confirmed by medical history and, if possible, compared to medical records.
- •Current and previous diagnosis of mania, bipolar disorder, psychosis, severe agitation, imminent deliria, current suicide risk, alcohol or drug dependence (ICD-10). Confirmed by psychiatric history and, if possible, compared to psychiatric or medical records.
- •Pregnancy and lactation.
- •MR & MEG scanner incompatibility, assessed by an MR/MEG control questionnaire.
- •After the beginning of the study;
- •MRI diagnosis of incidental pathologic findings; Lesions, Hemorrhage, etc.
- •The onset of acute depression or serve anxiety. Relevant transference to treatment option should be initiated immediately.
- •Suicide risk (treatment will be initiated immediately).
- •Pregnancy and lactation.
- •The patient wishes to leave the study.
- •The patient cannot co-operate during the examination.
研究组 & 干预措施
Patients with multiple chemical sensitivity (MCS)
MCS is characterized by odour intolerance and various somatic symptoms attributed to the influence of toxic environmental chemicals in low usually harmless doses.
干预措施: MRI and paraclinical tests (Diagnostic Test)
Patients with multi-systemic functional somatic disorders (FSD)
Based on empirical research, a phenotype of multi-systemic FSD or multi-organ bodily distress syndrome (multi-organ BDS) has been identified in the most severely affected patients who have symptoms from multiple organ systems, thus fulfilling the criteria for multiple FSS. Multi-organ BDS is a research diagnosis, and the terms FSD and BDS are used as synonyms. This diagnosis is defined by an identifiable physical symptom pattern with symptoms from four groups (a cardiopulmonary, a gastrointestinal, a musculoskeletal, and a general symptom group).
干预措施: MRI and paraclinical tests (Diagnostic Test)
Healthy controls
Healthy participants
干预措施: MRI and paraclinical tests (Diagnostic Test)
Patients with post-covid
Post covid is according to WHO characterized by continuation og development of new symptom 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation. Symptoms include fatigue, shortness of breath and cognitive dysfunction over 200 different symptoms have been reported that can have an impact on everyday functioning.
干预措施: MRI and paraclinical tests (Diagnostic Test)
结局指标
主要结局
"Fingerprinting"
时间窗: Through study completion, an average of 6 months
The investigators seek to employ whole-brain computational modeling based on MRI-derived functional and structural connectomes. The investigators will use the 3T MR Siemens® scanner that is situated at Aarhus University Hospital. A T1 structural image sequence will be run to obtain an image for later co-registration. After scanning data analyses including pre-processing, first-level analyses, and higher-level analyses will carry out.
"Sniffing Stick test"
时间窗: Through study completion, an average of 6 months.
The standardized psychophysical olfactory test, the "Sniffing Stick" test; will be performed on all three groups of participants before the scanning session. This battery of tests consists of odor threshold (T), discrimination (D), and identification (I) parts. The total score (TDI) was determined by the sum of the three scores (T+D+I). Habituation test; In order to test the flexible hedonic evaluation of odors in MCS and BDS compare to healthy controls the investigators will carry out habituation tests. The evaluation task asks the participant to rate the odors pleasantness, all individuals responses will be arranged by Likert scale 1-5.
次要结局
- Cognitive testing(Through study completion, an average of 6 months.)
- Pain thresholds(Through study completion, an average of 3 months.)
- Heart Rate Variability(Through study completion, an average of 6 months.)
